File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Serum MicroRNA Signature Predicts Response to High-Dose Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer

TitleSerum MicroRNA Signature Predicts Response to High-Dose Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer
Authors
Issue Date2018
Citation
International Journal of Radiation Oncology Biology Physics, 2018, v. 100, n. 1, p. 107-114 How to Cite?
Abstract© 2017 Elsevier Inc. Purpose To assess the utility of circulating serum microRNAs (c-miRNAs) to predict response to high-dose radiation therapy for locally advanced non-small cell lung cancer (NSCLC). Methods and Materials Data from 80 patients treated from 2004 to 2013 with definitive standard- or high-dose radiation therapy for stages II-III NSCLC as part of 4 prospective institutional clinical trials were evaluated. Pretreatment serum levels of 62 miRNAs were measured by quantitative reverse transcription–polymerase chain reaction array. We combined miRNA data and clinical factors to generate a dose–response score (DRS) for predicting overall survival (OS) after high-dose versus standard-dose radiation therapy. Elastic net Cox regression was used for variable selection and parameter estimation. Model assessment and tuning parameter selection were performed through full cross-validation. The DRS was also correlated with local progression, distant metastasis, and grade 3 or higher cardiac toxicity using Cox regression, and grade 2 or higher esophageal and pulmonary toxicity using logistic regression. Results Eleven predictive miRNAs were combined with clinical factors to generate a DRS for each patient. In patients with low DRS, high-dose radiation therapy was associated with significantly improved OS compared to treatment with standard-dose radiation therapy (hazard ratio 0.22). In these patients, high-dose radiation also conferred lower risk of distant metastasis and local progression, although the latter association was not statistically significant. Patients with high DRS exhibited similar rates of OS regardless of dose (hazard ratio 0.78). The DRS did not correlate with treatment-related toxicity. Conclusions Using c-miRNA signature and clinical factors, we developed a DRS that identified a subset of patients with locally advanced NSCLC who derive an OS benefit from high-dose radiation therapy. This DRS may guide dose escalation in a patient-specific manner.
Persistent Identifierhttp://hdl.handle.net/10722/267080
ISSN
2017 Impact Factor: 5.554
2015 SCImago Journal Rankings: 2.274
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorSun, Yilun-
dc.contributor.authorHawkins, Peter G.-
dc.contributor.authorBi, Nan-
dc.contributor.authorDess, Robert T.-
dc.contributor.authorTewari, Muneesh-
dc.contributor.authorHearn, Jason W.D.-
dc.contributor.authorHayman, James A.-
dc.contributor.authorKalemkerian, Gregory P.-
dc.contributor.authorLawrence, Theodore S.-
dc.contributor.authorTen Haken, Randall K.-
dc.contributor.authorMatuszak, Martha M.-
dc.contributor.authorKong, Feng Ming-
dc.contributor.authorJolly, Shruti-
dc.contributor.authorSchipper, Matthew J.-
dc.date.accessioned2019-01-31T07:20:27Z-
dc.date.available2019-01-31T07:20:27Z-
dc.date.issued2018-
dc.identifier.citationInternational Journal of Radiation Oncology Biology Physics, 2018, v. 100, n. 1, p. 107-114-
dc.identifier.issn0360-3016-
dc.identifier.urihttp://hdl.handle.net/10722/267080-
dc.description.abstract© 2017 Elsevier Inc. Purpose To assess the utility of circulating serum microRNAs (c-miRNAs) to predict response to high-dose radiation therapy for locally advanced non-small cell lung cancer (NSCLC). Methods and Materials Data from 80 patients treated from 2004 to 2013 with definitive standard- or high-dose radiation therapy for stages II-III NSCLC as part of 4 prospective institutional clinical trials were evaluated. Pretreatment serum levels of 62 miRNAs were measured by quantitative reverse transcription–polymerase chain reaction array. We combined miRNA data and clinical factors to generate a dose–response score (DRS) for predicting overall survival (OS) after high-dose versus standard-dose radiation therapy. Elastic net Cox regression was used for variable selection and parameter estimation. Model assessment and tuning parameter selection were performed through full cross-validation. The DRS was also correlated with local progression, distant metastasis, and grade 3 or higher cardiac toxicity using Cox regression, and grade 2 or higher esophageal and pulmonary toxicity using logistic regression. Results Eleven predictive miRNAs were combined with clinical factors to generate a DRS for each patient. In patients with low DRS, high-dose radiation therapy was associated with significantly improved OS compared to treatment with standard-dose radiation therapy (hazard ratio 0.22). In these patients, high-dose radiation also conferred lower risk of distant metastasis and local progression, although the latter association was not statistically significant. Patients with high DRS exhibited similar rates of OS regardless of dose (hazard ratio 0.78). The DRS did not correlate with treatment-related toxicity. Conclusions Using c-miRNA signature and clinical factors, we developed a DRS that identified a subset of patients with locally advanced NSCLC who derive an OS benefit from high-dose radiation therapy. This DRS may guide dose escalation in a patient-specific manner.-
dc.languageeng-
dc.relation.ispartofInternational Journal of Radiation Oncology Biology Physics-
dc.titleSerum MicroRNA Signature Predicts Response to High-Dose Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.ijrobp.2017.08.039-
dc.identifier.pmid29051037-
dc.identifier.scopuseid_2-s2.0-85031702686-
dc.identifier.volume100-
dc.identifier.issue1-
dc.identifier.spage107-
dc.identifier.epage114-
dc.identifier.eissn1879-355X-
dc.identifier.isiWOS:000419097000020-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats